Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin Against Streptococcus pneumoniae Using Data from a Neutropenic Murine-Lung Infection Model.

Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.02606-18. doi: 10.1128/AAC.02606-18. [Epub ahead of print]

PMID:
31182534
2.

Population Pharmacokinetic Analyses for Arbekacin After Administration of ME1100 Inhalation Solution.

Lakota EA, Sato N, Koresawa T, Kondo K, Bhavnani SM, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00267-19. doi: 10.1128/AAC.00267-19. [Epub ahead of print]

PMID:
31182524
3.

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, Bhavnani SM.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00318-19. doi: 10.1128/AAC.00318-19. Print 2019 Jun.

PMID:
30962339
4.

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.

Zhang L, Wicha WW, Bhavnani SM, Rubino CM.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii27-iii34. doi: 10.1093/jac/dkz088.

5.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.

Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii35-iii41. doi: 10.1093/jac/dkz089.

6.

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.

Rizk ML, Bhavnani SM, Drusano G, Dane A, Eakin AE, Guina T, Jang SH, Tomayko JF, Wang J, Zhuang L, Lodise TP.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02309-18. doi: 10.1128/AAC.02309-18. Print 2019 May. Review.

7.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02329-18. doi: 10.1128/AAC.02329-18. Print 2019 Apr.

8.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

9.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
10.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
11.

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.

Lakota EA, Landersdorfer CB, Zhang L, Nafziger AN, Bertino JS Jr, Bhavnani SM, Forrest A.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00784-18. doi: 10.1128/AAC.00784-18. Print 2018 Oct.

12.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

13.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):351. doi: 10.1007/s10928-018-9572-2.

PMID:
29446052
14.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

15.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Ambrose PG, VanScoy BD, Adams J, Fikes S, Bader JC, Bhavnani SM, Rubino CM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02257-17. doi: 10.1128/AAC.02257-17. Print 2018 Apr.

16.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Mar 1;73(3):831. doi: 10.1093/jac/dky013. No abstract available.

PMID:
29340605
17.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

18.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448. Review. Erratum in: J Antimicrob Chemother. 2018 Mar 1;73(3):831.

PMID:
29304211
19.

Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.

Bhavnani SM, Rex JH.

Curr Opin Pharmacol. 2017 Oct;36:viii-xii. doi: 10.1016/j.coph.2017.11.008. No abstract available.

PMID:
29246371
20.

Clinical pharmacokinetic-pharmacodynamic analyses: a critical element for developing antibacterial agents.

Bhavnani SM, Hammel JP.

Curr Opin Pharmacol. 2017 Oct;36:124-129. doi: 10.1016/j.coph.2017.09.010. Epub 2017 Nov 16. Review.

PMID:
29154210
21.

Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.

Trang M, Dudley MN, Bhavnani SM.

Curr Opin Pharmacol. 2017 Oct;36:107-113. doi: 10.1016/j.coph.2017.09.009. Epub 2017 Nov 10. Review.

PMID:
29128853
22.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

23.

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00630-17. doi: 10.1128/AAC.00630-17. Print 2017 Dec.

24.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

25.

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Feb 14;:.

PMID:
28353185
26.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb.

27.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Ambrose PG, VanScoy B, Conde H, McCauley J, Rubino CM, Bhavnani SM.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01605-16. doi: 10.1128/AAC.01605-16. Print 2017 Jan.

28.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5141-5. doi: 10.1128/AAC.00355-16. Print 2016 Sep.

29.

Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.

VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3891-6. doi: 10.1128/AAC.02943-15. Print 2016 Jul.

30.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

31.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

32.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

33.

Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG.

Antimicrob Agents Chemother. 2015;59(6):3365-72. doi: 10.1128/AAC.00176-15. Epub 2015 Mar 30.

34.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

35.

Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.

Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):282-8. doi: 10.1128/AAC.02033-13. Epub 2014 Oct 27.

36.

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31. doi: 10.1128/AAC.02310-13. Epub 2014 Jul 28.

37.

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.

Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R.

Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31.

38.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

39.

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6348-50. doi: 10.1128/AAC.01748-13. Epub 2013 Sep 16.

40.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.

41.

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.

42.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.

Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.

J Clin Pharmacol. 2013 Nov;53(11):1155-67. doi: 10.1002/jcph.153. Epub 2013 Aug 14.

PMID:
23907740
43.

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.

Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17.

44.

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3478-87. doi: 10.1128/AAC.02440-12. Epub 2013 May 13.

45.

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.

46.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.

47.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute.

Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18. Review.

PMID:
23334813
48.

Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jan;57(1):498-507. doi: 10.1128/AAC.01354-12. Epub 2012 Nov 12.

49.

New EMA guideline for antimicrobial development.

Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL.

Lancet Infect Dis. 2012 Apr;12(4):265-6. doi: 10.1016/S1473-3099(12)70046-4. No abstract available.

PMID:
22459079
50.

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.

Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12.

Supplemental Content

Loading ...
Support Center